Publications
The papers that built the field. Annotated references with links, no reproduced text.
Sebaa R et al. 2026. Multi-omics review: genomics, transcriptomics, proteomics, and metabolomics of adipose tissue; catalogs how each layer contributes to understanding adipocyte heterogeneity and disease association.
Zhang et al. 1994. The paper that made adipose tissue an endocrine organ. Leptin identified; field transformed.
Tontonoz, Hu, Spiegelman 1994. PPARgamma established as master regulator of adipocyte differentiation.
Nicholls 1976. UCP1 mechanism. Founding paper for the entire brown adipocyte thermogenesis field.
Scherer et al. 1995. Adiponectin discovered.
Hotamisligil, Shargill, Spiegelman 1993. Fat as an inflammatory organ.
Wu et al. 2012. Third adipocyte type defined with surface markers.
Steppan et al. 2001. Adipocyte-derived resistin promotes insulin resistance; neutralization improves glycaemia in obese mice.
Bjorntorp 1990. The portal hypothesis. Still the canonical reference for visceral fat risk.
Zimmermann et al. 2004. Rate-limiting triglyceride hydrolase in adipocytes identified.
Virtue and Vidal-Puig 2010. Unified model linking adipose capacity to systemic disease.
2025 scoping review. Catalogs every staining method used on fat and what each is actually informative for. The reference for stain selection decisions.
2026 review of therapeutic strategies targeting brown and beige adipocyte thermogenesis for obesity; covers beta-3 agonists, thyroid mimetics, and UCP1-independent routes.
Reviews UCP1-mediated thermogenesis in disease contexts: biomarker limitations, interindividual variation, and what prevents clinical translation.
New genetic tool for selectively targeting brown adipocytes in vivo; prior Cre lines had significant neuronal expression that confounded thermogenesis studies.
2026 review examining PPAR-gamma as both pro-adipogenic master regulator and context-sensitive modulator: why the same pathway drives healthy expansion and pathologic obesity.
Adipogenin's role in seipin-mediated lipid droplet enlargement as a new paradigm: LD architecture itself, not just lipid content, links to metabolic disease and cancer.